Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14476 - 14500 of 14602 in total
Experimental
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Description: … C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. …
BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27.
Experimental
Matched Description: … which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and
Deracoxib is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine to treat osteoarthritis in dogs. It is sold in tablets, which have added beefy flavour to increase palatability. Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with...
Vet approved
Matched Description: … Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation …
Experimental
Experimental
Vet approved
Experimental
ABT-384 has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.
Investigational
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Investigational
This compound belongs to the nitrofurans. These are compounds containing a furan ring which bears a nitro group. It targets the protein aldose reductase.
Experimental
Displaying drugs 14476 - 14500 of 14602 in total